# US 2025/0154148 A1 · Kras inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154148 A1
- Document ID: US20250154148A1
- Status: Published application
- Kind: A1
- Application number: 18/759,708
- Filed: 2024-06-28
- Published: 2025-05-15
- Earliest claimed: 2023-06-30
- Applicants: Bristol-Myers Squibb Company
- Inventors: Brian Edward FINK; Pravin S. SHIRUDE; Amit Kumar CHATTOPADHYAY; Laxmi Narayan NANDA; Vishweshwaraiah BALIGAR; Balaji SESHADRI; T.G. Murali DHAR; Li-Qiang SUN; Zhizhen Barbara ZHENG; Manoranjan PANDA; Maximilian David PALKOWITZ; Sirish Kaushik LAKKARAJU; Moloy BANERJEE
- Web page: https://patentgrep.com/patent/US20250154148A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/538: ortho- or peri-condensed with carbocyclic ring systems
- A61K 31/5386: spiro-condensed or forming part of bridged ring systems
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/554: having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A61P 35/00: Antineoplastic agents
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.

## Claims

### Claim 1

A compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
Y is O or SO2;
R1 is hydrogen, halo, ethynyl or ethyl;
R1′ is hydrogen, halo, or C1-3 alkyl;
R1″ is selected from hydrogen, C2-3alkenyl, C1-3 alkyl, C2-3 alkynyl, halo, and hydroxy;
R2 is hydrogen;
R3 is halo;
R4 and R5 are the same or different and each is hydrogen, C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, or C1-4 haloalkyl;
R20 is selected from hydrogen and hydroxyC1-4alkyl;
R6 is C1-6 alkyl optionally substituted with one or more deuterium atoms; C3-6 cycloalkyl optionally substituted with C1-C3alkoxy, C1-C3alkoxyC1-6 alkyl, amino, or cyanoethynyl; hydroxyC1-6 alkyl; haloC1-6 alkyl; hydroxy-haloC1-6 alkyl; methylsulfonylC1-C6alkyl; or —(CH2)n-A;
wherein A is a cyclic moiety selected from C3-6 cycloalkyl, C3-10 heterocycloalkyl, aryl, heteroaryl, spiro structures of any of these rings, and bicyclic structures of any of these rings, and n is 0, 1, 2, or 3;
wherein A is optionally substituted with one or more substituents selected from C1-4 alkyl, C1-4 alkylcarbonyl, C3-6 cycloalkylcarbonyl, hydroxy, halo, cyano, haloC1-6 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4alkyl, C1-4 alkoxycarbonyl, haloC1-4 alkoxycarbonyl, C1-4 alkylcarbamato, amido, C1-4 alkylamido, oxo, and methylsulfonyl; and
R7 and R8 are the same or different and each is hydrogen, hydroxy, C1-6 alkyl, C1-6 alkylsulfonyl, or halo.

### Claim at position 2

-6. (canceled)

### Claim 7

A compound of formula (II):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is ethynyl or ethyl;
R1′ is hydrogen or halo;
R1″ is selected from hydrogen, C2-3alkenyl, C1-3 alkyl, C2-3 alkynyl, halo, and hydroxy;
R2 is hydrogen;
R3 is halo;
R4, R5, R4′, and R5′ are the same or different and each is hydrogen, haloC1-4 alkyl, C1-4 alkyl, hydroxy, or hydroxyC1-4alkyl, or, R4′ and R5′, together with the atom to which they are attached, form a five-membered heterocycloalkyl ring optionally substituted with oxo;
R6 is C1-6 alkyl, hydroxyC1-6 alkyl, haloC1-6 alkyl, hydroxy-haloC1-6 alkyl, methylsulfonylC1-C6alkyl, or —(CH2)n-A;
wherein A is a cyclic moiety selected from C3-6 cycloalkyl, C3-7 heterocycloalkyl, spiro structures of either of these rings, and bicyclic structures of either of these rings, and n is 0, 1, or 2;
wherein A is optionally substituted with one or more substituents selected from C1-4 alkyl, C1-4 alkylcarbonyl, C3-6 cycloalkylcarbonyl, hydroxy, halo, haloC1-6 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4alkyl, C1-4 alkoxycarbonyl, haloC1-4 alkoxycarbonyl, C1-4 alkylcarbamato, amido, C1-4 alkylamido, oxo, and methylsulfonyl; and
R7 and R8 are the same or different and each is hydrogen, C1-6 alkyl, C1-6 alkylsulfonyl, or halo.

### Claim at position 4

-12. (canceled)

### Claim 13

A compound of formula (III):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is ethynyl or ethyl;
R1′ is hydrogen or halo;
R1″ is selected from hydrogen, C2-3alkenyl, C1-3 alkyl, C2-3 alkynyl, halo, and hydroxy;
R2 is hydrogen;
R3 is halo;
R6 is C1-6 alkyl, hydroxyC1-6 alkyl, haloC1-6 alkyl, hydroxy-haloC1-6 alkyl, methylsulfonylC1-C6alkyl, or —(CH2)n-A;
wherein A is a cyclic moiety selected from C3-6 cycloalkyl, C3-7 heterocycloalkyl, spiro structures of either of these rings, and bicyclic structures of either of these rings, and n is 0, 1, or 2;
wherein A is optionally substituted with one or more substituents selected from C1-4 alkyl, C1-4 alkylcarbonyl, C3-6 cycloalkylcarbonyl, hydroxy, halo, hydroxyC1-6 alkyl, haloC1-6 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4alkyl, C1-4 alkoxycarbonyl, haloC1-4 alkoxycarbonyl, C1-4 alkylcarbamato, amido, C1-4 alkylamido, oxo, and methylsulfonyl; and
R7 and R8 are the same or different and each is hydrogen, C1-6 alkyl, C1-6 alkylsulfonyl, or halo.

### Claim at position 6

-18. (canceled)

### Claim 19

A compound of formula (IV):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is ethynyl or ethyl;
R1′ is hydrogen or halo;
R1″ is selected from hydrogen, C2-3alkenyl, C1-3 alkyl, C2-3 alkynyl, halo, and hydroxy;
R2 is hydrogen;
R3 is halo;
R6 is C1-6 alkyl, hydroxyC1-6 alkyl, haloC1-6 alkyl, hydroxy-haloC1-6 alkyl, methylsulfonylC1-C6alkyl, or —(CH2)n-A;
wherein A is a cyclic moiety selected from C3-6 cycloalkyl, C3-7 heterocycloalkyl, spiro structures of either of these rings, and bicyclic structures of either of these rings, and n is 0, 1, or 2;
wherein A is optionally substituted with one or more substituents selected from C1-4 alkyl, C1-4 alkylcarbonyl, C3-6 cycloalkylcarbonyl, hydroxy, halo, haloC1-6 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4alkyl, C1-4 alkoxycarbonyl, haloC1-4 alkoxycarbonyl, C1-4 alkylcarbamato, amido, C1-4 alkylamido, oxo, and methylsulfonyl; and
R7 and R8 are the same or different and each is hydrogen, C1-6 alkyl, C1-6 alkylsulfonyl, or halo.

### Claim at position 8

-24. (canceled)

### Claim 25

A compound of formula (V):
or a pharmaceutically acceptable salt thereof, wherein:
Y is O or SO2;
R1 and R1′ are the same or different and each is hydrogen, halo, C1-4 alkyl, C2-4 alkenyl, C3-6 cycloalkyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy;
R2 is hydrogen;
R3 is halo;
R4 and R5 are the same or different and each is hydrogen, C1-4 alkyl, or hydroxy;
R20 is selected from hydrogen and hydroxyC1-4alkyl;
R6 is C1-6 alkyl, hydroxyC1-6 alkyl, haloC1-6 alkyl, hydroxy-haloC1-6 alkyl, methylsulfonylC1-C6alkyl, or —(CH2)n-A;
wherein A is a cyclic moiety selected from C3-6 cycloalkyl, C3-7 heterocycloalkyl, spiro structures of either of these rings, and bicyclic structures of either of these rings, and n is 0, 1, or 2;
wherein A is optionally substituted with one or more substituents selected from C1-4 alkyl, C1-4 alkylcarbonyl, cyano, C3-6 cycloalkylcarbonyl, hydroxy, halo, haloC1-6 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4alkyl, C1-4 alkoxycarbonyl, haloC1-4 alkoxycarbonyl, C1-4 alkylcarbamato, amido, C1-4 alkylamido, oxo, hydroxy C1-4alkyl, and methylsulfonyl; and
R7 and R8 are the same or different and each is hydrogen, C1-6 alkyl, C1-6 alkylsulfonyl, or halo.

### Claim at position 10

-29. (canceled)

### Claim 30

A compound of formula (VI):
or a pharmaceutically acceptable salt thereof, wherein:
R1 and R1′ are the same or different and each is hydrogen, halo, C1-4 alkyl, C3-6 cycloalkyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy;
R2 is hydrogen;
R3 is halo;
R4, R5, R4′, and R5′ are the same or different and each is hydrogen, haloC1-4 alkyl, C1-4 alkyl, hydroxy, or hydroxyC1-4alkyl, or, R4′ and R5′, together with the atom to which they are attached, form a five-membered heterocycloalkyl ring optionally substituted with oxo;
R6 is C1-6 alkyl, hydroxyC1-6 alkyl, haloC1-6 alkyl, hydroxy-haloC1-6 alkyl, methylsulfonylC1-C6alkyl, or —(CH2)n-A;
wherein A is a cyclic moiety selected from C3-6 cycloalkyl, C3-7 heterocycloalkyl, spiro structures of either of these rings, and bicyclic structures of either of these rings, and n is 0, 1, or 2;
wherein A is optionally substituted with one or more substituents selected from C1-4 alkyl, C1-4 alkylcarbonyl, C3-6 cycloalkylcarbonyl, hydroxy, halo, haloC1-6 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4alkyl, C1-4 alkoxycarbonyl, haloC1-4 alkoxycarbonyl, C1-4 alkylcarbamato, amido, C1-4 alkylamido, oxo, and methylsulfonyl; and
R7 and R8 are the same or different and each is hydrogen, C1-6 alkyl, C1-6 alkylsulfonyl, or halo.

### Claim at position 12

-34. (canceled)

### Claim 35

A compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof.

### Claim 36

A compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof.

### Claim 37

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 38

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 39 (depends on 35)

A pharmaceutical composition comprising a compound of claim 35, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

### Claim 40 (depends on 35)

An oral dosage form comprising a compound of claim 35, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

### Claim 41 (depends on 35)

A method of inhibiting KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D and/or KRAS Q61H in a subject in need thereof, the method comprising administering to the subject a compound of claim 35, or a pharmaceutically acceptable salt thereof.

### Claim 42 (depends on 35)

A method for treating a cancer susceptible to KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D and/or KRAS Q61H inhibition in a subject in need thereof, the method comprising administering to the subject a compound of claim 35, or a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 35)

A method for treating a cancer expressing a KRAS mutation and/or a KRAS copy number amplification in a subject in need thereof, the method comprising administering to the subject a compound of claim 35, or a pharmaceutically acceptable salt thereof.

### Claim 44 (depends on 35)

A method for treating a cancer expressing a KRAS G13R, Q61R, A146T, A146V, A59G, G12A, G12C, G12D, G12R, G12S, G12V, G13C, G13D, Q61H, Q61K, and/or a KRAS Q61L mutation, and/or a KRAS copy number amplification, in a subject in need thereof, the method comprising administering to the subject a compound of claim 35, or a pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 35)

A method for treating a cancer expressing KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D, and/or KRAS Q61H mutation in a subject in need thereof, the method comprising administering to the subject a compound of claim 35, or a pharmaceutically acceptable salt thereof.

### Claim 46 (depends on 35)

A method for treating a cancer in a subject in need thereof, the method comprising administering to the subject a compound of claim 35, or a pharmaceutically acceptable salt thereof.

### Claim 47 (depends on 46)

The method of claim 46, wherein the cancer is pancreatic cancer, colorectal cancer, lung cancer, gastric cancer, breast cancer, bladder cancer, cervical cancer, ovarian cancer, cancer of the uterus, or a combination thereof.

### Claim 48 (depends on 47)

The method of claim 47, wherein the cancer is pancreatic cancer, colorectal cancer, or non-small cell lung cancer.
